Table 2.
Distribution of tumour stage, tumour grade, and treatment in men with prostate cancer according to allocation to screening or no screening (control). Figures are numbers (percentages)
| No screening group | Screening group | |||
|---|---|---|---|---|
| All cancers | Cancers detected at screening | Interval cancers | ||
| Tumour stage: | ||||
| Localised tumours (T1-2, N0/NX, and M0) | 78 (26.7) | 48 (56.5) | 36 (83.7) | 12 (28.6) |
| Advanced tumours (T3-4, N1, or MX/M1) | 213 (73.3) | 37 (43.5) | 7 (16.3) | 30 (71.4) |
| Tumour grade: | ||||
| G1 | 94 (32.2) | 43 (50.6) | 24 (55.8) | 19 (45.2) |
| G2 | 149 (51.0) | 31 (36.5) | 19 (44.2) | 12 (28.6) |
| G3 | 43 (14.7) | 11 (12.9) | 0 (0) | 11 (26.2) |
| GX/tumour grade not recorded | 6 (2.1) | 0 (0) | 0 (0) | 0 (0) |
| Treatment: | ||||
| Watchful waiting | 101 (34.6) | 37 (43.5) | 21 (48.8) | 16 (38.1) |
| Hormonal treatment | 147 (50.3) | 27 (31.8) | 4 (9.3) | 23 (54.8) |
| Radical prostatectomy | 23 (7.9) | 16 (18.8) | 14 (32.6) | 2 (4.8) |
| Brachytherapy | 3 (1.0) | 1 (1.2) | 0 (0) | 1 (2.4) |
| External radiotherapy | 15 (5.1) | 4 (4.7) | 4 (9.3) | 0 (0) |
| Not registered | 3 (1.0) | 0 (0) | 0 (0) | 0 (0) |